| Not Yet Recruiting | A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) NCT07496567 | EyeBiotech Ltd. | Phase 2 / Phase 3 |
| Recruiting | A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) NCT07440225 | EyeBiotech Ltd. | Phase 2 / Phase 3 |
| Completed | A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Ma NCT06190093 | Outlook Therapeutics, Inc. | Phase 3 |
| Unknown | Artificial Intelligence Diagnostic Aid NCT05675540 | Guy's and St Thomas' NHS Foundation Trust | — |
| Completed | A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascul NCT05637255 | Sylentis, S.A. | Phase 2 |
| Completed | Mechanisms of Retinal Revascularization and Clinical Indicators of Neovascular AMD Relapse NCT05211804 | Sorlandet Hospital HF | — |
| Active Not Recruiting | A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual I NCT05112861 | Outlook Therapeutics, Inc. | Phase 3 |
| Terminated | Connective Tissue Growth Factor in Patients With Neovascular Age Related Macular Degeneration NCT05038371 | Johns Hopkins University | — |
| Completed | RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD) NCT04832724 | AbbVie | Phase 2 |
| Withdrawn | Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation NCT04698850 | Faculty Hospital Kralovske Vinohrady | Phase 4 |
| Completed | A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders NCT04516278 | Outlook Therapeutics, Inc. | Phase 3 |
| Active Not Recruiting | Optimizing the Treatment Strategy for Age-related Macular Degeneration NCT04420923 | St. Olavs Hospital | N/A |
| Terminated | A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Afl NCT04049266 | Kodiak Sciences Inc | Phase 2 / Phase 3 |
| Completed | A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular De NCT03861234 | Boehringer Ingelheim | Phase 1 / Phase 2 |
| Completed | A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age- NCT03834753 | Outlook Therapeutics, Inc. | Phase 3 |
| Completed | Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD NCT03954626 | Novartis Pharmaceuticals | Phase 3 |
| Enrolling By Invitation | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy NCT03999801 | AbbVie | Phase 2 |
| Terminated | Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration NCT03699618 | Johns Hopkins University | — |
| Completed | A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular NCT03823300 | Hoffmann-La Roche | Phase 3 |
| Completed | A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular NCT03823287 | Hoffmann-La Roche | Phase 3 |
| Completed | A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age- NCT03844074 | Outlook Therapeutics, Inc. | Phase 3 |
| Terminated | Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related NCT03452527 | Iconic Therapeutics, Inc. | Phase 2 |
| Unknown | Management of Patients With Neovascular Age-related Macular Degeneration Undergoing Cataract Surgery NCT03944070 | Ophthalmica Eye Institute | N/A |
| Completed | The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-li NCT03278262 | Bayer | — |
| Completed | Ziv-aflibercept Efficacy in Better Regulating AMD NCT03423823 | Kapil Kapoor | Phase 2 |
| Completed | The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy NCT03022292 | University of California, Los Angeles | Phase 4 |
| Completed | Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related NCT03034772 | Wills Eye | Phase 2 / Phase 3 |
| Unknown | Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vascul NCT02806752 | Aier School of Ophthalmology, Central South University | Phase 4 |
| Completed | Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration NCT02944227 | Seoul National University Hospital | Phase 4 |
| Completed | Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD NCT02321241 | Bayer | — |
| Completed | To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Pat NCT02540369 | Bayer | — |
| Completed | Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan NCT02541084 | Bayer | — |
| Completed | Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME. NCT02571972 | Wills Eye | Phase 2 |
| Completed | Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Ital NCT02289924 | Bayer | — |
| Completed | Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration NCT02305238 | Bayer | Phase 4 |
| Completed | Study of Nutritional Supplementation in Patients With Unilateral Wet AMD NCT04756310 | Laboratorios Thea, Spain | N/A |
| Completed | A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration NCT02121522 | Boehringer Ingelheim | Phase 2 |
| Completed | EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection NCT02689518 | University of California, San Diego | Phase 4 |
| Completed | Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD NCT02279537 | Bayer | — |
| Completed | Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration NCT02157077 | Centre Hospitalier Intercommunal Creteil | Phase 3 |
| Completed | Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Respond NCT01896284 | Barcelona Macula Foundation | Phase 4 |
| Completed | Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration NCT02060604 | Università degli Studi di Brescia | Phase 4 |
| Unknown | An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovasc NCT01521065 | Oraya Therapeutics, Inc. | Phase 2 |
| Completed | Non-Persistence/Non-Adherence (NP/NA) in Wet Age-related Macular Degeneration (wAMD) Patients in Germany NCT01448538 | Bayer | — |
| Completed | OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab NCT01243086 | McMaster University | Phase 2 |
| Unknown | Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab NCT01249937 | University Health Network, Toronto | Phase 2 |
| Completed | Reading Speed Improvements in Wet-AMD Patients After Ranibizumab Treatment NCT04982484 | Centre Hospitalier Régional Metz-Thionville | — |
| Terminated | HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration NCT01189019 | Anne Fung MD | Phase 2 |
| Completed | Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments NCT00590694 | Pacific Eye Associates | Phase 2 / Phase 3 |
| Completed | A Population-based Study of Macular Choroidal Neovascularization in a Chinese Population NCT01666821 | Shanghai University of Traditional Chinese Medicine | — |